Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 479 All time
- Disclosed funding
- $19.6B 405 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| TB Develops novel therapeutics for glaucoma and retinal diseases | $17M | Series A | Biotech | United States | Investors | |
| C ContralineCompany profile Develops hormonal and non-hormonal male contraceptives for men and couples globally Develops hormonal and non-hormonal male contraceptives for men and couples globally | $92.5M | Series B | Biotech | United States | Investors | |
| N NovelliaCompany profile Platform that unifies patient health records for individuals and supplies anonymized data to pharma researchers Platform that unifies patient health records for individuals and supplies anonymized data to pharma researchers | $18M | Series A | Biotech, Healthtech | United States | Investors | |
| WB Waypoint BioCompany profile Develops AI-designed CAR T therapies for solid tumors using spatial biology Develops AI-designed CAR T therapies for solid tumors using spatial biology | $20M | Series A | Biotech | United States | Investors | |
| CL Develops single-molecule PCR technology for genomics measurement | $26M | Series A | Biotech | United States | Investors | |
| T TriomicsCompany profile Building AI infrastructure to turn complex cancer records into structured intelligence Building AI infrastructure to turn complex cancer records into structured intelligence | $22M | Series B | Biotech, Healthtech | United States | Investors | |
| P PsileraCompany profile Develops next-generation neuroplastogens and psychedelic therapies for neurological conditions Develops next-generation neuroplastogens and psychedelic therapies for neurological conditions | $8.8M | Seed+Seed | Biotech | United States | Investors Undisclosed | |
| ST Secretome TherapeuticsCompany profile Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy | $30M | Series A | Biotech | United States | Investors | |
| PB Protuoso BiosciencesCompany profile Develops AI-enabled multifunctional biologics platform targeting cardiometabolic, oncology, and autoimmune diseases Develops AI-enabled multifunctional biologics platform targeting cardiometabolic, oncology, and autoimmune diseases | $9.5M | Seed | Biotech | United States | Investors | |
| CH ClearNote HealthCompany profile Develops noninvasive blood-based early detection tests for pancreatic and ovarian cancers Develops noninvasive blood-based early detection tests for pancreatic and ovarian cancers | $52M | Series DSeries C+ | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →